View Alert


Originator: CMO Messaging

From: Professor Stephen Powis, Professor Gillian Leng, Dr June Raine

Issue date: 14-Apr-2020 17:15:36

This alert has been issued to:
  • NHS Regional Offices
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive
  • NHS Trusts (England) - Medical Director
  • NHS Trusts (England) - Chief Executive

  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • Social Care Providers (registered with CAS)
  • Special Health Authorities
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • Consultants in Communicable Diseases
  • CMO Urgent Messages - Recipients on Public Health Link
  • Director of Public Health
  • GP - Locum
  • NHS 111 and Out of hours providers
  • GP Practices
  • Out of hours contacts
  • Primary Care Networks

Action category: Important information for immediate action

Title: Ibuprofen and coronavirus (COVID-19)

Broadcast content:

The Commission on Human Medicines’ Expert Working Group on coronavirus (COVID-19) has concluded that there is currently insufficient evidence to establish a link between use of ibuprofen, or other non-steroidal anti-inflammatory drugs (NSAIDs), and contracting or worsening of COVID-19.

The attached alert provides further information.



Additional information: NHS England Regional Offices: please cascade to Community Pharmacy, Dental, Optometry and any GP Practices not registered with CAS.

Alert reference: CEM/CMO/2020/017

Attachments:

Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency